Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bio-Rad Laboratories Inc.

    NYSE: BIO · Real-Time Price · USD
    229.09
    -1.27 (-0.55%)
    At close: May 28, 2025, 3:59 PM
    232.16
    1.34%
    After-hours: May 28, 2025, 07:46 PM EDT
    -0.55%
    Bid 217
    Market Cap 6.25B
    Revenue (ttm) 2.54B
    Net Income (ttm) -2.23B
    EPS (ttm) -76.53
    PE Ratio (ttm) -2.99
    Forward PE 22.6
    Analyst Buy
    Ask 245.6
    Volume 216,184
    Avg. Volume (20D) 373,955
    Open 229.75
    Previous Close 230.36
    Day's Range 227.76 - 230.62
    52-Week Range 215.38 - 387.99
    Beta 1.00

    About BIO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BIO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    -1.5%
    Bio-Rad Laboratories shares are trading higher aft... Unlock content with Pro Subscription
    3 months ago
    -1.92%
    Bio-Rad Laboratories shares are trading lower after the company missed Q4 revenue estimates.
    news image

    2 weeks ago · zacks.com

    Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

    Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

    news image

    2 weeks ago · businesswire.com

    Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

    HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv...

    news image

    3 weeks ago · businesswire.com

    KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON

    NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

    news image

    3 weeks ago · zacks.com

    BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

    Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.

    news image

    3 weeks ago · seekingalpha.com

    Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

    Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Opera...

    news image

    3 weeks ago · zacks.com

    Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

    Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.

    news image

    3 weeks ago · businesswire.com

    Bio-Rad Reports First-Quarter 2025 Financial Results

    HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

    news image

    1 month ago · zacks.com

    Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

    Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · zacks.com

    Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

    BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

    news image

    2 months ago · prismmediawire.com

    Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

    IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth q...

    Add to Watchlist